CY1111687T1 - Χρηση των αναστολεων il-18 - Google Patents

Χρηση των αναστολεων il-18

Info

Publication number
CY1111687T1
CY1111687T1 CY20111100682T CY111100682T CY1111687T1 CY 1111687 T1 CY1111687 T1 CY 1111687T1 CY 20111100682 T CY20111100682 T CY 20111100682T CY 111100682 T CY111100682 T CY 111100682T CY 1111687 T1 CY1111687 T1 CY 1111687T1
Authority
CY
Cyprus
Prior art keywords
inhibitors
medicament
prevention
manufacture
treatment
Prior art date
Application number
CY20111100682T
Other languages
English (en)
Inventor
Yolande Chvatchko
Charles Dinarello
Christine Plater-Zyberk
DEVENTER Santer VAN
Menachem Rubinstein
Daniela Novick
Soo-Hyun Kim
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1111687T1 publication Critical patent/CY1111687T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η εφεύρεση σχετίζεται με τη χρήση των αναστολέων IL-18 στην παρασκευή ενός φαρμάκου για τη θεραπεία και/ή την πρόληψη της ηπατικής βλάβης. Η εφεύρεση σχετίζεται περαιτέρω με τη χρήση των αναστολέων IL-18 στην παρασκευή ενός φαρμάκου για τη θεραπεία και/ή την πρόληψη της αρθρίτιδας, και συγκεκριμένα της ρευματοειδούς αρθρίτιδας. Επιπλέον, η εφεύρεση σχετίζεται με τη χρήση των αναστολέων IL-18 στην παρασκευή ενός φαρμάκου για τη θεραπεία και/ή την πρόληψη της φλεγμονώδους νόσου του παχέος εντέρου, και συγκεκριμένα της νόσου του Crohn και της ελκώδους κολίτιδας.
CY20111100682T 2000-02-21 2011-07-13 Χρηση των αναστολεων il-18 CY1111687T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103597 2000-02-21
EP00103590 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
EP01911662A EP1257292B1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
CY1111687T1 true CY1111687T1 (el) 2015-10-07

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100682T CY1111687T1 (el) 2000-02-21 2011-07-13 Χρηση των αναστολεων il-18

Country Status (31)

Country Link
US (1) US20030157094A1 (el)
EP (1) EP1257292B1 (el)
JP (1) JP4744763B2 (el)
KR (3) KR20070057282A (el)
CN (1) CN1322897C (el)
AT (1) ATE506959T1 (el)
AU (2) AU2001240636B8 (el)
BG (1) BG66134B1 (el)
BR (1) BR0108514A (el)
CA (2) CA2683009C (el)
CY (1) CY1111687T1 (el)
CZ (1) CZ304485B6 (el)
DE (1) DE60144514D1 (el)
DK (1) DK1257292T3 (el)
EA (1) EA005583B1 (el)
EE (1) EE05423B1 (el)
HK (1) HK1051965A1 (el)
HR (1) HRP20020652A2 (el)
HU (1) HU227752B1 (el)
IL (2) IL151388A0 (el)
ME (1) ME00546B (el)
MX (1) MXPA02008079A (el)
NO (1) NO331971B1 (el)
NZ (3) NZ546294A (el)
PL (1) PL206549B1 (el)
PT (1) PT1257292E (el)
RS (1) RS51737B (el)
SI (1) SI1257292T1 (el)
SK (1) SK288032B6 (el)
TR (2) TR200202030T2 (el)
WO (1) WO2001062285A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
HU227752B1 (en) * 2000-02-21 2012-02-28 Yeda Res & Dev Use of il-18 inhibitors
EP2357002A1 (en) 2000-10-11 2011-08-17 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
WO2003045400A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
EP1587530A2 (en) * 2003-01-20 2005-10-26 VIB vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
CA2523912A1 (en) 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
AU2004290413A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1780542A4 (en) 2004-06-30 2008-05-14 Atsuo Sekiyama AGENT INDICATING A NON-INFLAMMATORY RESPONSE TO A STRESS AND USE THEREOF
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
SI1885753T1 (sl) 2005-06-03 2011-12-30 Ares Trading Sa Proizvodnja rekombinantnega il-18 vezavnega proteina
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Ｉｌ−１８結合タンパク質の精製のための方法
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
SG172625A1 (en) 2006-05-25 2011-07-28 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
MX2016002719A (es) 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
EP3265807A1 (en) 2015-03-05 2018-01-10 AB2 Bio SA Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
US20210115131A1 (en) * 2018-06-14 2021-04-22 Université De Bordeaux Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0936923B1 (en) * 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18 BINDING PROTEIN
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
HU227752B1 (en) * 2000-02-21 2012-02-28 Yeda Res & Dev Use of il-18 inhibitors
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
KR20020086540A (ko) 2002-11-18
HUP0300061A3 (en) 2005-09-28
PL357554A1 (en) 2004-07-26
EP1257292B1 (en) 2011-04-27
EE200200463A (et) 2003-12-15
NO20023962L (no) 2002-08-20
CN1322897C (zh) 2007-06-27
DE60144514D1 (de) 2011-06-09
HRP20020652A2 (en) 2004-12-31
EA200200890A1 (ru) 2003-02-27
TR200202030T2 (tr) 2003-01-21
JP2003523403A (ja) 2003-08-05
CZ20022843A3 (cs) 2003-02-12
SK288032B6 (sk) 2012-12-03
PT1257292E (pt) 2011-07-05
HU227752B1 (en) 2012-02-28
NO20023962D0 (no) 2002-08-20
PL206549B1 (pl) 2010-08-31
NZ520122A (en) 2005-04-29
IL151388A0 (en) 2003-04-10
EA005583B1 (ru) 2005-04-28
HK1051965A1 (en) 2003-08-29
CA2399298A1 (en) 2001-08-30
CZ304485B6 (cs) 2014-05-28
ME00546B (me) 2011-10-10
IL151388A (en) 2009-09-01
SK12082002A3 (sk) 2003-05-02
EP1257292A1 (en) 2002-11-20
YU60402A (sh) 2005-09-19
DK1257292T3 (da) 2011-07-18
BG66134B1 (bg) 2011-06-30
KR20070087256A (ko) 2007-08-27
RS51737B (sr) 2011-10-31
HUP0300061A2 (hu) 2003-04-28
NZ535299A (en) 2006-06-30
AU2001240636B2 (en) 2005-10-13
AU2001240636B8 (en) 2005-11-03
MXPA02008079A (es) 2003-02-27
CN1404400A (zh) 2003-03-19
BR0108514A (pt) 2002-12-17
US20030157094A1 (en) 2003-08-21
KR20070057282A (ko) 2007-06-04
TR200502508T2 (tr) 2007-04-24
ATE506959T1 (de) 2011-05-15
AU4063601A (en) 2001-09-03
NO331971B1 (no) 2012-05-14
WO2001062285A1 (en) 2001-08-30
EE05423B1 (et) 2011-06-15
CA2683009C (en) 2014-09-23
CA2683009A1 (en) 2001-08-30
JP4744763B2 (ja) 2011-08-10
NZ546294A (en) 2008-02-29
CA2399298C (en) 2014-04-15
SI1257292T1 (sl) 2011-08-31
BG107018A (bg) 2003-09-30

Similar Documents

Publication Publication Date Title
CY1111687T1 (el) Χρηση των αναστολεων il-18
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
CY2013004I2 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
CY1111246T1 (el) Προληψη και θεραπεια επαγομενης απο φλεγμονη και/ή ανοσοδιαμεσολαβουμενης οστικης απωλειας
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
CY1107687T1 (el) Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
ITMI20010957A0 (it) Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
ITMI20001113A0 (it) Iniziatori organici e loro impiego nella polimerizzazione di monomeriinsaturi.
Harrison BS EN 206-1/BS 8500 basics: consistence.
ITRM20000300A0 (it) Bendaggio infustito per protezione e/o immobilizzazione del piede e delle sue articolazioni.
UA37656A (uk) Спосіб створення гепатикоєюностомії
FI20000303A0 (fi) Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
TR200003529A3 (tr) Insan iliginin bagisiklik tahlili ve mezkurun kullanimiyla çoklu sklerozun teshisi.